170 related articles for article (PubMed ID: 29800673)
1. Long-term follow-up of de novo chronic phase chronic myelogenous leukemia patients on front-line imatinib.
Nicolini FE; Alcazer V; Cony-Makhoul P; Heiblig M; Morisset S; Fossard G; Bidet A; Schmitt A; Sobh M; Hayette S; Mahon FX; Dulucq S; Etienne G
Exp Hematol; 2018 Aug; 64():97-105.e4. PubMed ID: 29800673
[TBL] [Abstract][Full Text] [Related]
2. Chronic myeloid leukemia patients in Tunisia: epidemiology and outcome in the imatinib era (a multicentric experience).
Ben Lakhal R; Ghedira H; Bellaaj H; Ben Youssef Y; Menif S; Manai Z; Bedoui M; Lakhal A; M'Sadek F; Elloumi M; Khélif A; Ben Romdhane N; Laatiri MA; Ben Othmen T; Meddeb B
Ann Hematol; 2018 Apr; 97(4):597-604. PubMed ID: 29305630
[TBL] [Abstract][Full Text] [Related]
3. Pattern of chronic myeloid leukemia in the imatinib era in a Sub-Saharan African setting.
Faye BF; Dieng N; Seck M; Gadji M; Gueye YB; Sy D; Toure SA; Sall A; Toure AO; Dieye TN; Diop S
Ann Hematol; 2016 Oct; 95(10):1603-10. PubMed ID: 27370991
[TBL] [Abstract][Full Text] [Related]
4. Long-Term Outcomes after Imatinib Mesylate Discontinuation in Chronic Myeloid Leukemia Patients with Undetectable Minimal Residual Disease.
Yhim HY; Lee NR; Song EK; Yim CY; Jeon SY; Lee B; Kim JA; Kim HS; Cho EH; Kwak JY
Acta Haematol; 2016; 135(3):133-9. PubMed ID: 26535871
[TBL] [Abstract][Full Text] [Related]
5. Imatinib mesylate as first-line therapy in patients with chronic myeloid leukemia in accelerated phase and blast phase: a retrospective analysis.
Thota NK; Gundeti S; Linga VG; Coca P; Tara RP;
Indian J Cancer; 2014; 51(1):5-9. PubMed ID: 24947087
[TBL] [Abstract][Full Text] [Related]
6. Real-world Imatinib Mesylate Treatment in Patients with Chronic Myeloid Leukemia: The Importance of Molecular Monitoring and the Early Molecular Response.
Ferreira APS; Seguro FS; Abdo ARN; Santos FM; Maciel FVR; Nardinelli L; Giorgi RR; Ruiz ARL; Ferreira MPS; Rego EM; Rocha V; Bendit I
Ann Hematol; 2023 Jul; 102(7):1761-1771. PubMed ID: 37052662
[TBL] [Abstract][Full Text] [Related]
7. Lymphocytosis after treatment with dasatinib in chronic myeloid leukemia: Effects on response and toxicity.
Schiffer CA; Cortes JE; Hochhaus A; Saglio G; le Coutre P; Porkka K; Mustjoki S; Mohamed H; Shah NP
Cancer; 2016 May; 122(9):1398-407. PubMed ID: 26998677
[TBL] [Abstract][Full Text] [Related]
8. Reduced-intensity allogeneic hematopoietic stem cell transplantation combined with imatinib has comparable event-free survival and overall survival to long-term imatinib treatment in young patients with chronic myeloid leukemia.
Zhao Y; Wang J; Luo Y; Shi J; Zheng W; Tan Y; Cai Z; Huang H
Ann Hematol; 2017 Aug; 96(8):1353-1360. PubMed ID: 28624905
[TBL] [Abstract][Full Text] [Related]
9. Long term outcome of chronic myeloid leukemia patients treated with imatinib: Report from a developing country.
Absar M; Akhtar T; Jameel A; Mahmood A; Ullah A; Aleem A; Qureshi K; Rehman N; Iqbal Z
Pak J Pharm Sci; 2020 Mar; 33(2(Supplementary)):861-870. PubMed ID: 32863263
[TBL] [Abstract][Full Text] [Related]
10. Ten-year outcome of chronic-phase chronic myeloid leukemia patients treated with imatinib in real life.
Molica M; Colafigli G; Scalzulli E; Alunni Fegatelli D; Chiatamone Ranieri S; Rizzo L; Diverio D; Efficace F; Latagliata R; Foà R; Breccia M
Ann Hematol; 2019 Aug; 98(8):1891-1904. PubMed ID: 31079264
[TBL] [Abstract][Full Text] [Related]
11. Diagnosis and Treatment of Chronic Myeloid Leukemia in the Imatinib Mesylate Era: Report of the Experience at "La Raza" Medical Center in Mexico.
Ayala M; Ávila E; Domínguez J; Aquino X; Vela J
Clin Lymphoma Myeloma Leuk; 2016 Feb; 16(2):57-62. PubMed ID: 26699851
[TBL] [Abstract][Full Text] [Related]
12. Comparative Effectiveness of Newer Tyrosine Kinase Inhibitors Versus Imatinib in the First-Line Treatment of Chronic-Phase Chronic Myeloid Leukemia Across Risk Groups: A Systematic Review and Meta-Analysis of Eight Randomized Trials.
Yun S; Vincelette ND; Segar JM; Dong Y; Shen Y; Kim DW; Abraham I
Clin Lymphoma Myeloma Leuk; 2016 Jun; 16(6):e85-94. PubMed ID: 27101984
[TBL] [Abstract][Full Text] [Related]
13. Factors influencing long-term efficacy and tolerability of bosutinib in chronic phase chronic myeloid leukaemia resistant or intolerant to imatinib.
Brümmendorf TH; Cortes JE; Khoury HJ; Kantarjian HM; Kim DW; Schafhausen P; Conlan MG; Shapiro M; Turnbull K; Leip E; Gambacorti-Passerini C; Lipton JH
Br J Haematol; 2016 Jan; 172(1):97-110. PubMed ID: 26537529
[TBL] [Abstract][Full Text] [Related]
14. Cross-Intolerance With Dasatinib Among Imatinib-Intolerant Patients With Chronic Phase Chronic Myeloid Leukemia.
Khoury HJ; Goldberg SL; Mauro MJ; Stone RM; Deininger MW; Bradley-Garelik MB; Mohamed H; Guilhot F
Clin Lymphoma Myeloma Leuk; 2016 Jun; 16(6):341-349.e1. PubMed ID: 27133948
[TBL] [Abstract][Full Text] [Related]
15. Systematic Review and Meta-Analysis of -New-Generation Tyrosine Kinase Inhibitors versus Imatinib for Newly Diagnosed Chronic Myeloid Leukemia.
Pan P; Wang L; Wang Y; Shen L; Zheng P; Bi C; Zhang A; Lv Y; Xue Z; Sun M; Sun C; Li J; Jin L; Yao Y
Acta Haematol; 2020; 143(3):204-216. PubMed ID: 31514197
[TBL] [Abstract][Full Text] [Related]
16. Evaluation of Residual Disease and TKI Duration Are Critical Predictive Factors for Molecular Recurrence after Stopping Imatinib First-line in Chronic Phase CML Patients.
Nicolini FE; Dulucq S; Boureau L; Cony-Makhoul P; Charbonnier A; Escoffre-Barbe M; Rigal-Huguet F; Coiteux V; Varet B; Dubruille V; Lenain P; Rousselot P; Rea D; Guerci-Bresler A; Legros L; Liu J; Gardembas M; Ianotto JC; Turlure P; Johnson-Ansah H; Martiniuc J; Jardel H; Joly B; Zunic P; Henni T; Villemagne B; Berger MG; Cayssials E; Guilhot F; Larosa F; Guilhot J; Etienne G; Mahon FX
Clin Cancer Res; 2019 Nov; 25(22):6606-6613. PubMed ID: 31292142
[TBL] [Abstract][Full Text] [Related]
17. Advanced phase chronic myeloid leukaemia (CML) in the tyrosine kinase inhibitor era - a report from the Swedish CML register.
Söderlund S; Dahlén T; Sandin F; Olsson-Strömberg U; Creignou M; Dreimane A; Lübking A; Markevärn B; Själander A; Wadenvik H; Stenke L; Richter J; Höglund M
Eur J Haematol; 2017 Jan; 98(1):57-66. PubMed ID: 27428357
[TBL] [Abstract][Full Text] [Related]
18. Five-year follow-up of patients treated with imatinib mesylate for chronic myeloid leukaemia in Trinidad and Tobago.
Charles KS; Ramon L; Leelah N; Oluwabusi TA; Seemungal T
West Indian Med J; 2011 Jun; 60(3):298-302. PubMed ID: 22224342
[TBL] [Abstract][Full Text] [Related]
19. [Comparison of the efficacy and safety of Chinese generic imatinib and branded imatinib in patients with chronic myeloid leukemia in consideration of demographic characteristics].
Dou XL; Yu L; Qin YZ; Shi HX; Lai YY; Hou Y; Huang XJ; Jiang Q
Zhonghua Xue Ye Xue Za Zhi; 2019 Nov; 40(11):924-931. PubMed ID: 31856442
[No Abstract] [Full Text] [Related]
20. A prospective analysis of clinical efficacy and safety in chronic myeloid leukemia-chronic phase patients with imatinib resistance or intolerance as evaluated using European LeukemiaNet 2013 criteria.
Murai K; Akagi T; Shimosegawa K; Sugawara T; Ishizawa K; Ito S; Murai K; Motegi M; Yokoyama H; Noji H; Tajima K; Kimura J; Chou T; Ogawa K; Harigae H; Kubo K; Oba K; Sakamoto J; Ishida Y
Eur J Haematol; 2015 Dec; 95(6):558-65. PubMed ID: 25703064
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
